Twenty analysts rate Pfizer with an average “Hold” recommendation, including one sell, thirteen hold, four buy, and two strong buy ratings, setting a mean 12-month price target of $27.88. The firm reported $0.87 EPS versus $0.79 consensus on $16.65 billion revenue.